36 results on '"Michaeli, Daniel Tobias"'
Search Results
2. Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs
3. Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition
4. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
5. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
6. Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
7. Gene regulation for inflammation and inflammation resolution differs between umbilical arterial and venous endothelial cells
8. Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending
9. Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology
10. Value drivers of development stage biopharma companies
11. Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland
12. Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
13. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
14. Socio-economic burden of disease: Survivorship costs for bladder cancer
15. Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa
16. Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and Investors
17. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
18. The Healthcare Workforce Shortage of Nurses and Physicians: Practice, Theory, Evidence, and Ways Forward.
19. Clinical benefit, development, innovation, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations.
20. Clinical benefit, development, innovation, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations
21. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
22. Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications
23. Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021
24. Socio-economic burden of disease: survivorship costs for soft tissue sarcoma
25. Socio‐economic burden of disease: Survivorship costs for renal cell carcinoma
26. Differential Effects of Omega-3 Fatty Acids on HO-1, VCAM-1, and Cytotoxicity in Endothelial Cells
27. Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
28. Association of SARS-CoV-2 vaccinations and personal protective measures with seroconversion and risk of infection in a large real-world cohort of patients with cancer.
29. Clinical evidence and benefit of special FDA designations in anti-cancer drugs.
30. Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland
31. Cost-effectiveness of bivalent, quadrivalent, and nonavalent HPV vaccination in South Africa
32. Advances in cancer therapy: clinical benefit of new cancer drugs
33. WITHDRAWN: Differential Effects of Omega-3 Fatty Acids on HO-1, VCAM-1, and Cytotoxicity in Endothelial Cells
34. Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications.
35. Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price.
36. Advances in cancer therapy: clinical benefit of new cancer drugs.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.